Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Bone diseases

Romosozumab — on track or derailed?

Romosozumab, a recently developed sclerostin inhibitor, stimulates bone formation and inhibits bone resorption, thereby markedly increasing bone mass and reducing fracture risk. But will a red flag regarding possible adverse cardiovascular events derail this promising new drug for osteoporosis?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Khosla, S. & Hofbauer, L. C. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. http://dx.doi.org/10.1016/s2213-8587(17)30188-2 (2017).

  2. 2

    Brunkow, M. E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577–589 (2001).

    CAS  Article  Google Scholar 

  3. 3

    Khosla, S., Westendorf, J. J. & Oursler, M. J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421–428 (2008).

    CAS  Article  Google Scholar 

  4. 4

    Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).

    CAS  Article  Google Scholar 

  5. 5

    McClung, M. R. et al. Romosozumab in postmenopausal women with low bone mineral density. N. Engl. J. Med. 370, 412–420 (2014).

    CAS  Article  Google Scholar 

  6. 6

    Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532–1543 (2016).

    CAS  Article  Google Scholar 

  7. 7

    Saag, K. G. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1708322 (2017).

  8. 8

    Rosen, C. J. Romosozumab — promising or practice changing? N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMe1711298 (2017).

  9. 9

    Tanko, L. B. et al. Relationship between osteoporosis and cardiovascular disease in postmenopausal women. J. Bone. Miner. Res. 20, 1912–1920 (2005).

    Article  Google Scholar 

  10. 10

    Gay, A. & Towler, D. A. Wnt signaling in cardiovascular disease: opportunities and challenges. Curr. Opin. Lipidol. 28, 387–396 (2017).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The author's work is supported by NIH grants AG004875, AG048792 and AR027065. In addition, the author greatly appreciates the critical review of this article by M. Drake and J. Farr.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Sundeep Khosla.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Khosla, S. Romosozumab — on track or derailed?. Nat Rev Endocrinol 13, 697–698 (2017). https://doi.org/10.1038/nrendo.2017.136

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing